Tech Company Financing Transactions
I-Mab Biopharma Funding Round
I-Mab Biopharma closed a $220 million Series C investment round on 6/30/2018. Backers included Hony Capital, Ally Bridge Group and C-Bridge Capital.
Transaction Overview
Company Name
Announced On
6/30/2018
Transaction Type
Venture Equity
Amount
$220,000,000
Round
Series C
Investors
Hony Capital (Lead Investor) (Bing Yuan)
C-Bridge Capital (Wei Fu)
Proceeds Purpose
The proceeds of the financing will be used primarily to advance the pre-clinical and clinical development of a number of Best-in-Class and First-in-Class assets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
West Tower OmniVision 88 Shangke Rd. Pudong District 802
Shanghai, 201210
China
Shanghai, 201210
China
Phone
Website
Email Address
Overview
I-Mab Biopharma was established through a merger of Third Venture Biopharma, an innovative antibody start-up, and Tasgen, a joint venture biotech by Tasly Pharmaceuticals, Genexine and C-Bridge Capital.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jingwu Zang
Chief Executive Officer
Joan Shen
Chief Financial Officer
Jielun Zhu
General Manager
Neil Warma
Vice President
Douglas Chen
Vice President
Lili Qian
VP - Bus. Development
Raven Lin
VP - Bus. Development
Weimin Tang
VP - Manufacturing
Zheru Zhang
Browse more venture capital transactions:
Prev: 6/30/2018: Silverfort venture capital transaction
Next: 6/30/2018: TrendKite venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs